Cancer stem cells (CSCs) play an important role in
tumor initiation, progression, therapeutic failure and
tumor relapse. In this study, we evaluated the efficacy of the
thiazole derivative 3-methylcyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl]
hydrazone (CPTH6), a novel pCAF and Gcn5
histone acetyltransferase inhibitor, as a small molecule that preferentially targets
lung cancer stem-like cells (LCSCs) derived from
non-small cell lung cancer (NSCLC) patients. Notably, although CPTH6 inhibits the growth of both LCSC and NSCLC cell lines, LCSCs exhibit greater growth inhibition than established NSCLC cells. Growth inhibitory effect of CPTH6 in LCSC lines is primarily due to apoptosis induction. Of note, differentiated progeny of LCSC lines is more resistant to CPTH6 in terms of loss of cell viability and reduction of
protein acetylation, when compared to their undifferentiated counterparts. Interestingly, in LCSC lines CPTH6 treatment is also associated with a reduction of stemness markers. By using different HAT inhibitors we provide clear evidence that inhibition of HAT confers a strong preferential inhibitory effect on cell viability of undifferentiated LCSC lines when compared to their differentiated progeny. In vivo, CPTH6 is able to inhibit the growth of LCSC-derived xenografts and to reduce cancer stem cell content in treated
tumors, as evidenced by marked reduction of
tumor-initiating capacity in limiting dilution assays. Strikingly, the ability of CPTH6 to inhibit
tubulin acetylation is also confirmed in vivo. Overall, our studies propose
histone acetyltransferase inhibition as an attractive target for
cancer therapy of NSCLC.